Home Business End of the pandemic, for the CEO of Moderna we are now...

End of the pandemic, for the CEO of Moderna we are now close


There end of the pandemic it might be close. Directions in this direction come from Moderna CEO Stephane Bancel, who deems “reasonable” one such scenario. He confirmed this during an interview with CNBC, explaining that “there is an 80% chance that the new variants are less virulent than Omicron”.

Beyond the virulence of the virus, the number one of Moderna is convinced, “that this virus will not go away completely, it will remain like the flu and we should live with it“. In January, the US company announced it had launched a clinical trial to study the safety and efficacy of a Covid vaccine booster that specifically targets Omicron variant.

End of the pandemic: caution from the WHO

But not everyone is as optimistic as Moderna’s number one about the end of the pandemic. In January, the head of the World Health Organization, Tedros Adhanom Ghebreyesus, warned that it is dangerous to assume that the pandemic is in its final stages. “It’s not over at all,” she thundered, warning that new variants are likely to emerge as Omicron quickly spreads around the world. Similar caution has come from the White House advisor on COVID, Anthony Fauci, that it is still an “open question” that the omicron variant will mark the final wave of the pandemic.

Read:   Opening Bell at 2.15pm: Ukraine, Attacco yes, indeed maybe….

According to theWorld Health Organizationin the past 7 days there have been 15.47 million new cases reported worldwide and 73,162 deaths.

Modern title misses

Meanwhile Moderna has begun the new year under pressure. Since January, the stock has left 35% on the ground. And now it is moving just above the lows of the year, reached on February 14, when the shares closed at 142 dollars.
The sales of this early 2022 of the year have led to -15% the increase to one year. On the other hand, the five-year performance remains largely positive (+ 712%).

Via agreement with Laboratorios Farmaceuticos Rovi

Today, meanwhile, the biotechnology company is a pioneer in therapies and moles RNA messenger vaccines (mRNA), and Laboratorios Farmaceuticos Rovi, a pan-European pharmaceutical company specializing in the research, development, contract manufacturing and commercialization of small molecules and biological specialties, have announced a long-term collaboration to increase compounding, aseptic filling, inspection capabilities. , labeling and packaging of the ROVI factories, located in MadridSan Sebastian de los Reyes and Alcala ‘de Henares.

Read:   Quirinal election: how much Mattarella's successor will earn

This ten-year agreement includes a series of investments which should allow for an increase in ROVI production capacity in Madrid, Spain. In addition to producing Moderna’s Covid-19 vaccine, ROVI’s platform could also be used for future Moderna mRna vaccine candidates.

Previous articleEnd of Operation “Barkhane”: the painful lessons of France in Mali
Next articleCrisis Ukraine, Russia towards withdrawal? Political leaders and NATO are cautious